Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis

Clinical and Experimental Immunology

Volumn 172, Issue 1, 2013, Pages 37-43

  Uzawa, A ^a   Mori, M ^a   Taniguchi, J ^a   Masuda, S ^a   Muto, M ^a   Kuwabara, S ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Cytokine; Experimental autoimmune encephalomyelitis; High mobility group box 1; Monoclonal antibody; Multiple sclerosis

Indexed keywords

CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP BOX 1 ANTIBODY; INTERLEUKIN 17; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION; HMGB1 PROTEIN; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEUROPROTECTIVE AGENTS; SEVERITY OF ILLNESS INDEX; SPINAL CORD;

EID: 84875002286     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12036     Document Type: Article

References (36)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502-1517.
2. Polman CH, Reingold SC, Edan G etal. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58:840-846.
3. Kappos L, Antel J, Comi G etal. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355:1124-1140.
4. Hawker K, O'Connor P, Freedman MS etal. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66:460-471.
5. Coles AJ, Fox E, Vladic A etal. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78:1069-1078.
6. Polman CH, O'Connor PW, Havrdova E etal. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
7. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006; 7:774-778.
8. Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 1996; 54:35-100.
9. Fiuza C, Bustin M, Talwar S etal. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101:2652-2660.
10. Bell CW, Jiang W, Reich CF III etal. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291:C1318-1325.
11. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418:191-195.
12. Kokkola R, Andersson A, Mullins G etal. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61:1-9.
13. Yang H, Hreggvidsdottir HS, Palmblad K etal. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107:11942-11947.
14. Park JS, Svetkauskatie D, He Q etal. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279:7370-7377.
15. Tian J, Avalos AM, Mao SY etal. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8:487-496.
16. Park JS, Gamboni-Robertson F, He Q etal. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290:C917-924.
17. Avalos AM, Kiefer K, Tian J etal. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity 2010; 43:103-110.
18. Rouhiainen A, Kuja-Panula J, Wilkman E etal. Regulation of monocyte migration by amphoterin (HMGB1). Blood 2004; 104:1174-1182.
19. Andersson U, Wang H, Palmblad K etal. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192:565-570.
20. Ek M, Popovic K, Harris HE etal. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006; 54:2289-2294.
21. Taira T, Matsuyama W, Mitsuyama H etal. Increased serum high mobility group box-1 level in Churg-Strauss syndrome. Clin Exp Immunol 2007; 148:241-247.
22. Taniguchi N, Kawahara K, Yone K etal. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48:971-981.
23. Urbonaviciute V, Furnrohr BG, Meister S etal. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205:3007-3018.
24. Andersson A, Covacu R, Sunnemark D etal. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008; 84:1248-1255.
25. Abdulahad DA, Westra J, Bijzet J etal. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011; 13:R71.
26. Uzawa A, Mori M, Masuda S etal. CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2012. doi: 10.1136/jnnp-2012-304039.
27. Humle Jorgensen S, Sorensen PS. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J Neurol Sci 2005; 233:61-65.
28. Ishizu T, Osoegawa M, Mei FJ etal. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128:988-1002.
29. Lock C, Hermans G, Pedotti R etal. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8:500-508.
30. Komiyama Y, Nakae S, Matsuki T etal. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177:566-573.
31. Quintana A, Müller M, Frausto RF etal. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol 2009; 183:2079-2088.
32. Eugster HP, Frei K, Kopf M etal. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998; 28:2178-2187.
33. Liu K, Mori S, Takahashi HK etal. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 2007; 21:3904-3916.
34. Zhang J, Takahashi HK, Liu K etal. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 2011; 42:1420-1428.
35. Schierbeck H, Lundbäck P, Palmblad K etal. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 2011; 17:1039-1044.
36. Su Z, Sun C, Zhou C etal. HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17-cell expansion. Eur J Immunol 2011; 41:3586-3595.